TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
TRACON Pharmaceuticals (TCON) will release its fourth quarter and full year 2020 financial results on February 25, 2021, after U.S. markets close. Following the report, management will hold a conference call at 4:30 PM ET to discuss financial and corporate updates. TCON focuses on developing targeted cancer therapeutics using an efficient, CRO-independent platform. Key products in their pipeline include Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors.
- Management will provide updates on corporate activities during the conference call.
- TCON is actively seeking corporate partnerships for U.S. regulatory and clinical development.
- A diverse pipeline of cancer therapeutics indicates broad market potential.
- None.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | February 25, 2021 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 5681569 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 212-915-2578 |
| mwiggins@traconpharma.com |
FAQ
When will TCON report its Q4 and full year 2020 financial results?
What time is the TCON conference call scheduled?
How can I access the TCON conference call?
What products are included in TRACON's pipeline?
Where can I find more information about TRACON Pharmaceuticals?
